6/14/2013 9:42:03 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
London, UK, 14 June 2013 – On 24 May 2013, Lombard Medical Technologies PLC (AIM:LMT) announced an issue of equity to raise GBP21.0 million (before expenses) by way of a Placing and Subscription. In conjunction with the Placing and Subscription, the Board also announced details of an Offer to Qualifying Participants to raise up to an additional GBP2.0 million (before expenses). The Board also announced that the Convertible Loan Notes issued to Invesco Asset Management Limited would be converted into ordinary shares.
The Board of Lombard Medical is pleased to announce that, at the General Meeting of the Company held earlier today, the resolutions which were set out in the Notice of General Meeting included in the circular to shareholders in relation to the Placing, Subscription and Offer dated 24 May 2013 were duly passed.
Application has been made for 14,541,375 New Ordinary Shares, being the total number of New Ordinary Shares being issued under the Placing and Subscription, the Offer and the conversion of the Convertible Loan Notes, to be admitted to trading on AIM. Admission is expected to become effective at 8:00a.m. on 17 June 2013. Following the admission of the Placing Shares, the Company will have 44,743,187 ordinary shares of 20 pence each in issue.
Definitions used in this announcement will have the same meaning as those used in the Circular, unless the context requires otherwise.
For further information:
Lombard Medical Technologies PLC Tel: 01235 750 800
Simon Hubbert, Chief Executive Officer
Ian Ardill, Chief Financial Officer
Canaccord Genuity Limited
Lucy Tilley / Tim Redfern / Henry Fitzgerald O’Connor / Dr Julian Feneley Tel: 020 7523 8000
David Wilson / Claes Spång Tel: 020 7149 3627
Simon Conway / Susan Stuart / Victoria Foster Mitchell Tel: 020 7831 3113
About Lombard Medical
Lombard Medical Technologies PLC (AIM: LMT), is a medical device company focused on device solutions for the $1.2 billion dollar per annum abdominal aortic aneurysm (AAA) repair market. AAAs are a balloon-like enlargement of the aorta which, if left untreated, may rupture and cause death. Approximately 4.5 million people are living with AAAs in the developed world and each year 600,000 new cases are diagnosed. The market for endovascular stent grafts for this application is expected to grow to $1.6 billion by 2015. The Company’s lead product, Aorfix™, is an endovascular stent graft which has been specifically designed to solve the problems that exist in treating complex tortuous anatomy which is often present in advanced AAA disease. Aorfix™ is currently being commercialised in the EU, and has been approved by the FDA in the U.S., the first AAA stent graft not of U.S. origin to gain FDA approval.
The Company is headquartered in Oxfordshire, with operations in Ayrshire and Phoenix, USA.
Further background on the Company can be found at www.lombardmedical.com.
F T I Consulting
+44 (0)20 7269 7121 direct
Holborn Gate, 26 Southampton Buildings
London, WC2A 1PB
Help employers find you! Check out all the jobs and post your resume.
comments powered by